Your browser doesn't support javascript.
loading
Clinical research analysis based on prostate cancer screening diagnosis.
Shan, Jiahao; Geng, Xinyu; Liu, Ziyang; Lu, Youlu; Zhou, Raorao; Zhang, Zhengyuan; Xu, Haoran; Zhou, Xiaojie; Ma, Wenzhuo; Zhu, Hengyu; Shi, Hongbin.
Afiliação
  • Shan J; Department of urology, Suzhou Hospital of Anhui Medical University, Suzhou, China.
  • Geng X; Department of urology, Suzhou Hospital of Anhui Medical University, Suzhou, China.
  • Liu Z; School of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
  • Lu Y; Department of urology, Suzhou Hospital of Anhui Medical University, Suzhou, China.
  • Zhou R; Department of urology, Suzhou Hospital of Anhui Medical University, Suzhou, China.
  • Zhang Z; Department of urology, Suzhou Hospital of Anhui Medical University, Suzhou, China.
  • Xu H; School of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
  • Zhou X; School of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
  • Ma W; School of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
  • Zhu H; Department of urology, General Hospital of Ningxia Medical University, Yinchuan, China.
  • Shi H; Department of urology, General Hospital of Ningxia Medical University, Yinchuan, China.
Andrologia ; 54(4): e14371, 2022 May.
Article em En | MEDLINE | ID: mdl-35014705
ABSTRACT
This study aimed to analyse the clinical characteristics and risk factors of patients with positive prostate biopsy at 4-20 ng/mL of prostate-specific antigen (PSA), construct a new parameter based on this characteristics and assess its diagnostic value for prostate cancer (PCa). Logistic regression analysis was used to clarify the risk factors of PCa, and a new parameter based on the results was constructed. Compare the diagnostic value of various diagnostic parameters for PCa. Logistic multivariate regression analysis revealed that age (OR, 5.269; 95%CI, 2.762-10.050), comorbid diabetes (OR, 2.437; 95%CI, 1.162-5.111), PSA (OR, 2.462; 95%CI, 1.198-5.059) and prostate volume (PV) (OR, 0.227; 95%CI, 0.100-0.516) are risk factors for PCa. The age, PSA and PV of patients were combined to construct a new parameter, that is A-PSAD = (age × total PSA [TPSA])/PV]. The area under the receiver-operating characteristic curve(AUC) of A-PSAD (0.728) for PCa diagnosis was higher than the AUCs of TPSA (0.581), free prostate-specific antigen (0.514), (F/T)PSA (0.535) and PSAD (0.696), with significant differences. Age, history of diabetes, TPSA and PV are risk factors for PCa(PSA4-20ng/mL); in addition, A-PSAD has a moderate diagnostic value for PCa and may become a new indicator for PCa screening.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article